Kamyar Farahi

411 total citations
7 papers, 300 citations indexed

About

Kamyar Farahi is a scholar working on Immunology, Complementary and alternative medicine and Dermatology. According to data from OpenAlex, Kamyar Farahi has authored 7 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 3 papers in Complementary and alternative medicine and 2 papers in Dermatology. Recurrent topics in Kamyar Farahi's work include Psoriasis: Treatment and Pathogenesis (6 papers), Complementary and Alternative Medicine Studies (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Kamyar Farahi is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (6 papers), Complementary and Alternative Medicine Studies (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Kamyar Farahi collaborates with scholars based in United States, Canada and Netherlands. Kamyar Farahi's co-authors include Chureen Carter, T. Michelle Brown, Brad Schenkel, David M. Pariser, Charles N. Ellis, Soumya D. Chakravarty, Subrata Ghosh, C Gasink, Lianne S. Gensler and Bruce Strober and has published in prestigious journals such as Journal of Investigative Dermatology, British Journal of Dermatology and Drug Safety.

In The Last Decade

Kamyar Farahi

7 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kamyar Farahi United States	7	209	150	50	39	38	7	300
Toshihiro Ito Japan	9	233 1.1×	130 0.9×	52 1.0×	25 0.6×	35 0.9×	15	294
H. Vázquez‐Veiga Spain	7	112 0.5×	102 0.7×	39 0.8×	14 0.4×	31 0.8×	27	204
L. Salgado‐Boquete Spain	10	178 0.9×	165 1.1×	36 0.7×	8 0.2×	49 1.3×	32	303
Osamu Fukuchi Japan	7	180 0.9×	114 0.8×	37 0.7×	24 0.6×	35 0.9×	11	236
Jolanta Węgłowska Poland	6	336 1.6×	152 1.0×	77 1.5×	22 0.6×	55 1.4×	16	437
Joachim Klaus Germany	7	93 0.4×	70 0.5×	23 0.5×	33 0.8×	37 1.0×	10	173
Ko Nakajo Japan	7	224 1.1×	172 1.1×	39 0.8×	16 0.4×	37 1.0×	18	325
Arvin Ighani Canada	12	228 1.1×	150 1.0×	34 0.7×	14 0.4×	18 0.5×	19	290
S. D’Adamio Italy	14	348 1.7×	235 1.6×	51 1.0×	18 0.5×	33 0.9×	23	451
Ting‐Shun Wang Taiwan	11	294 1.4×	178 1.2×	80 1.6×	11 0.3×	59 1.6×	18	384

Countries citing papers authored by Kamyar Farahi

Since Specialization

Citations

This map shows the geographic impact of Kamyar Farahi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamyar Farahi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamyar Farahi more than expected).

Fields of papers citing papers by Kamyar Farahi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamyar Farahi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamyar Farahi. The network helps show where Kamyar Farahi may publish in the future.

Co-authorship network of co-authors of Kamyar Farahi

This figure shows the co-authorship network connecting the top 25 collaborators of Kamyar Farahi. A scholar is included among the top collaborators of Kamyar Farahi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamyar Farahi. Kamyar Farahi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Ghosh, Subrata, Lianne S. Gensler, Zijiang Yang, et al.. (2019). Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety. 42(6). 751–768. 80 indexed citations

2.

Loesche, Michael A., Kamyar Farahi, Kimberly Capone, et al.. (2018). Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. Journal of Investigative Dermatology. 138(9). 1973–1981. 54 indexed citations

3.

Kavanaugh, Arthur, Kim Papp, Alice B. Gottlieb, et al.. (2018). Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry. BMC Rheumatology. 2(1). 29–29. 15 indexed citations

4.

Blauvelt, Andrew, Laura K. Ferris, Paul S. Yamauchi, et al.. (2017). Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). British Journal of Dermatology. 177(6). 1552–1561. 45 indexed citations

5.

Zhang, Mingliang, Chureen Carter, William H. Olson, et al.. (2017). Patient Preference for Dosing Frequency Based on Prior Biologic Experience.. PubMed. 16(3). 220–226. 10 indexed citations

6.

Zhang, Mingliang, Susan K. Brenneman, Chureen Carter, et al.. (2015). Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Preference and Adherence. 9. 777–777. 28 indexed citations

7.

Pariser, David M., Brad Schenkel, Chureen Carter, et al.. (2015). A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. Journal of Dermatological Treatment. 27(1). 19–26. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact